WO2023181010 - ANTI-WT1 ANTIGEN-BINDING PROTEINS AND USES THEREOF
National phase entry:
Publication Number
WO/2023/181010
Publication Date
28.09.2023
International Application No.
PCT/IB2023/052959
International Filing Date
24.03.2023
Title **
[English]
ANTI-WT1 ANTIGEN-BINDING PROTEINS AND USES THEREOF
[French]
PROTÉINES DE LIAISON À L'ANTIGÈNE ANTI-WT1 ET LEURS UTILISATIONS
Applicants **
UNIVERSITY HEALTH NETWORK
Inventors
HIRANO, Naoto
OCHI, Toshiki
WANG, Chung-Hsi
Priority Data
63/323,459
24.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5843 | |
| EPO | Filing, Examination, Granting | 87619 | |
| Japan | Filing, Examination, Granting | 4501 | |
| South Korea | Filing, Examination, Granting | 7190 | |
| USA | Filing, Examination, Granting | 27490 |
Total:
132,643
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure is directed to antigen-binding molecules that specifically bind peptide fragments of tumor antigens, wherein the peptide fragment is capable of being presented by more than one type of major histocompatibility complex (MHC) class II molecule. In some aspects, the tumor antigen is a WT1 polypeptide. Other aspects are directed to antibodies, multispecific antibodies, and chimeric antigen receptors, and nucleotides encoding the same. Other aspects are directed to methods of administering the same to a subject in need thereof.[French]
La présente divulgation concerne des molécules de liaison à l'antigène qui se lient de manière spécifique à des fragments peptidiques d'antigènes tumoraux, le fragment peptidique pouvant être présenté par plus d'un type de molécule de complexe majeur d'histocompatibilité (CMH) de classe II. Dans certains aspects, l'antigène tumoral est un polypeptide WT1. D'autres aspects concernent des anticorps, des anticorps multispécifiques, des récepteurs antigéniques chimériques et des nucléotides codant pour ceux-ci. D'autres aspects concernent leurs méthodes d'administration à un sujet en ayant besoin.